AC Immune’s (ACIU) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of AC Immune (NASDAQ:ACIU) in a research report sent to investors on Wednesday,Benzinga reports. They currently have a $16.00 target price on the stock. HC Wainwright also issued estimates for AC Immune’s Q4 2024 earnings at ($0.23) EPS, FY2024 earnings at ($0.62) EPS, FY2025 earnings at $0.41 EPS, FY2026 earnings at $0.75 EPS, FY2027 earnings at $1.36 EPS and FY2028 earnings at $1.95 EPS.

Separately, StockNews.com cut shares of AC Immune from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st.

AC Immune Stock Performance

Shares of ACIU opened at $3.20 on Wednesday. AC Immune has a one year low of $2.25 and a one year high of $5.14. The stock’s fifty day moving average is $3.27 and its 200-day moving average is $3.46. The firm has a market capitalization of $316.61 million, a price-to-earnings ratio of -6.96 and a beta of 1.28.

Hedge Funds Weigh In On AC Immune

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Silverberg Bernstein Capital Management LLC bought a new stake in shares of AC Immune in the 2nd quarter worth $40,000. Lazard Asset Management LLC acquired a new position in AC Immune during the first quarter worth about $30,000. BNP Paribas Financial Markets grew its holdings in AC Immune by 315.6% during the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock worth $33,000 after acquiring an additional 8,423 shares during the period. Vanguard Capital Wealth Advisors bought a new stake in AC Immune in the second quarter worth about $56,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in AC Immune by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock valued at $72,000 after acquiring an additional 7,400 shares during the last quarter. 51.36% of the stock is owned by institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.